As of June 12, 2025, Karo Pharma AB (KARO.ST) reports a ROE (Return on Equity) of -0.30%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Karo Pharma AB's ROE (Return on Equity)
Over recent years, Karo Pharma AB's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2021-12-31 | -0.30% |
| 2020-12-31 | 1.46% |
| 2019-12-31 | 0.16% |
| 2018-12-31 | 18.21% |
| 2017-12-31 | 0.91% |
This slight upward trend highlights how Karo Pharma AB manages its efficiency in generating profits from shareholders' equity over time.
Comparing Karo Pharma AB's ROE (Return on Equity) to Peers
To better understand Karo Pharma AB's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Karo Pharma AB (KARO.ST) | -0.30% |
| Orexo AB (ORX.ST) | 160.73% |
| Marinomed Biotech AG (MARI.VI) | 67.03% |
| Acacia Pharma Group PLC (ACPH.BR) | 34.72% |
| Cosmo Pharmaceuticals NV (COPN.SW) | 26.74% |
| Laboratorios Farmaceuticos ROVI SA (ROVI.MC) | 23.93% |
Compared to its competitors, Karo Pharma AB's ROE (Return on Equity) is about average compared to peers, reflecting standard industry returns on equity investment.